Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: Induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers

Vaccine

Volumn 20, Issue 29-30, 2002, Pages 3598-3612

  Jung, Maria Christina ^a,b   Grüner, Norbert ^a,b   Zachoval, Reinhart ^a   Schraut, Winfried ^b   Gerlach, Tilman ^a,b   Diepolder, Helmut ^a,b   Schirren, Carl Albrecht ^a   Page, Mark ^c   Bailey, John ^c   Birtles, Emma ^c   Whitehead, Eve ^c   Trojan, Jörg ^d   Zeuzem, Stefan ^d   Pape, Gerd R ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Medeva Pharma Limited   (United Kingdom)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Induction of T cell response; Therapeutic vaccine; Treatment in chronic HBV infection

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; LYMPHOKINE; NUCLEOCAPSID PROTEIN; RECOMBINANT HEPATITIS B VACCINE;

ANTIGENICITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG SPECIFICITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOLOGICAL MONITORING; LYMPHOCYTE PROLIFERATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INDUCTION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADULT; ALANINE TRANSAMINASE; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 0037019913     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00309-2     Document Type: Article

References (17)

1. Perrillo R.P. Interferon in the management of chronic hepatitis B. Dig. Dis. Sci. 38(4):1993;577-593.
2. Chisari FV. The immunobiology of viral hepatitis: T-lymphocytes in the liver. In: Crispe IN, editor. Immunobiology, Pathology, and Host Defense; 1999. p. 117-38.
3. Pol S., Driss F., Carnot F., Michel M.L., Berthelot P., Brechot C. Vaccination against hepatitis B virus: an efficient immunotherapy against hepatitis B multiplication. C R Acad. Sci. III. 316:1993;688-691.
4. Pol S., Driss F., Michel M.L., Nalpas B., Berthelot P., Brechot C. Specific vaccine therapy in chronic hepatitis infection. Lancet. 344:1994;342. [letter].
5. Jones C.D., Page M., Bacon A., Cahill E., Bentley M., Chatfield S.N. T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice. Vaccine. 17:1999;2528-2537.
6. ®). Intervirology. 44(2-3):2001;88-97.
7. Ferrari C., Penna A., Bertolletti A., Valli A., Antoni A.D., Giuberti T.et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol. 145:1990;3442-3449.
8. Jung M.-C., Diepolder H.M., Spengler U.et al. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J. Virol. 69:1995;3358-3368.
9. Maruyama T., McLachlan A., Lino S., Koike K., Kurokawa K., Milich D.R. The serology of chronic hepatitis B revisited. J. Clin. Invest. 91:1993;2586-2595.
10. Wen Y.M., Wu X.H., Hu D.C., Zhang Q.P., Gno S.Q. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet. 345:1995;1575-1576.
11. McDermott A.B., Madrigal J.A., Sabin C.A., Zuckerman J.N., Cohen S.B.A. The influence of host factors and immunogenetics on lymphocyte responses to Hepagene vaccination. Vaccine. 17:1999;1329-1337.
12. McDermott I., Cohen S.B.A., Zuckerman J.N., Madrigal J.A. Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine. 17:1999;330-339.
13. Couillin I., Pol S., Mancini M., Driss F., Brechot C., Tiollais P.et al. Specific vaccine therapy in chronic hepatitis B: induction of T-cell proliferative responses specific for envelope antigens. J. Infect. Dis. 180:1999;15-26.
14. Matloubian M., Conception R.J., Ahmed R. CD4+ T-cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:1994;8056-8063.
15. Livingston B.D., Crimi C., Grey H.et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159:1997;1383-1392.
16. Boni C., Bertoletti A., Penna A.et al. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102:1998;968-975.
17. Ferrari C., Bertoletti A., Penna A.et al. Identification of immunodominant T-cell epitopes of the hepatitis B virus nucleocapsid antigen. J. Clin. Invest. 88:1991;214-222.